Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02)

Abstract Background Dacomitinib is the second‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) for mutant non–small cell lung cancer (NSCLC). EGFR‐TKIs are often re‐administered in Japan after the disease progression prior EGFR‐TKI. There is little evidence of dacom...

詳細記述

保存先:
書誌詳細
主要な著者: Hisashi Tanaka, Hiroaki Sakamoto, Takahiro Akita, Fumiyoshi Ohyanagi, Yosuke Kawashima, Yuichi Tambo, Azusa Tanimoto, Atsushi Horiike, Eisaku Miyauchi, Yuko Tsuchiya‐Kawano, Noriko Yanagitani, Makoto Nishio
フォーマット: Artigo
言語:Inglês
出版事項: Wiley 2022-05-01
シリーズ:Thoracic Cancer
主題:
dacomitinib
epidermal growth factor receptor mutation
exon 21 L858R
non‐small cell lung cancer
rechallenge
オンライン･アクセス:https://doi.org/10.1111/1759-7714.14415
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料